AU2010329805B2 - New conjugates and compositions for immunotherapy and anti-tumoral treatment - Google Patents

New conjugates and compositions for immunotherapy and anti-tumoral treatment

Info

Publication number
AU2010329805B2
AU2010329805B2 AU2010329805A AU2010329805A AU2010329805B2 AU 2010329805 B2 AU2010329805 B2 AU 2010329805B2 AU 2010329805 A AU2010329805 A AU 2010329805A AU 2010329805 A AU2010329805 A AU 2010329805A AU 2010329805 B2 AU2010329805 B2 AU 2010329805B2
Authority
AU
Australia
Prior art keywords
identity
functionally equivalent
polypeptide
equivalent variant
apo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010329805A
Other languages
English (en)
Other versions
AU2010329805A1 (en
Inventor
Pedro Berraondo Lopez
Silvia Bulfone-Paus
Erwin Hans Duitman
Jessica Fioravanti
Jose Medina Echeverz
Ignacio Javier Melero Bermejo
Maria Del Carmen Ochoa Nieto
Francisco De Asis Palazon Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Center Borstel - Leibniz Lung Center
Proyecto de Biomedicina CIMA SL
Original Assignee
Research Center Borstel - Leibniz Lung Center
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200931158A external-priority patent/ES2362062B1/es
Application filed by Research Center Borstel - Leibniz Lung Center, Proyecto de Biomedicina CIMA SL filed Critical Research Center Borstel - Leibniz Lung Center
Publication of AU2010329805A1 publication Critical patent/AU2010329805A1/en
Application granted granted Critical
Publication of AU2010329805B2 publication Critical patent/AU2010329805B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010329805A 2009-12-11 2010-12-10 New conjugates and compositions for immunotherapy and anti-tumoral treatment Ceased AU2010329805B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ES200931158A ES2362062B1 (es) 2009-12-11 2009-12-11 Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.
ESP200931158 2009-12-11
ESP201030813 2010-05-27
ES201030813 2010-05-27
PCT/ES2010/070818 WO2011070214A2 (es) 2009-12-11 2010-12-10 Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral

Publications (2)

Publication Number Publication Date
AU2010329805A1 AU2010329805A1 (en) 2012-07-05
AU2010329805B2 true AU2010329805B2 (en) 2016-07-14

Family

ID=43927978

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010329805A Ceased AU2010329805B2 (en) 2009-12-11 2010-12-10 New conjugates and compositions for immunotherapy and anti-tumoral treatment

Country Status (11)

Country Link
US (1) US8771664B2 (enExample)
EP (1) EP2511294B1 (enExample)
JP (1) JP5784626B2 (enExample)
CN (1) CN102753574B (enExample)
AU (1) AU2010329805B2 (enExample)
BR (1) BR112012013868A8 (enExample)
CA (1) CA2783876C (enExample)
ES (1) ES2463016T3 (enExample)
MX (1) MX2012006691A (enExample)
RU (1) RU2597989C2 (enExample)
WO (1) WO2011070214A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
JP2016518361A (ja) * 2013-04-19 2016-06-23 シーチューヌ ファルマＣｙｔｕｎｅ Ｐｈａｒｍａ 血管漏出症候群の発生を抑制するサイトカイン治療
WO2015054701A2 (en) * 2013-10-13 2015-04-16 Nova Southeastern University Analyzing immune signaling networks for identification of therapeutic targets in complex chronic medical disorders, identification of a natural killer cell population as a potential therapeutic target for gulf war illness & myalgic encephalomyelitis/chronic fatigue syndrome, and modulation of natural killer cell function by stimulation with interleukin 15
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
LT3094351T (lt) * 2014-01-15 2022-04-11 Kadmon Corporation, Llc Imunitetą moduliuojantys agentai
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
WO2015164107A1 (en) 2014-04-23 2015-10-29 Emory University Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto
US12577323B2 (en) 2015-06-10 2026-03-17 Emory University Compositions and conjugates comprising an interleukin and polypeptides that specifically bind TGF-beta
CN106317225A (zh) * 2015-06-28 2017-01-11 复旦大学 具有靶向性长效白细胞介素22融合蛋白及其制备方法和用途
EP3978512A1 (en) 2015-10-09 2022-04-06 Bioniz, LLC Modulating gamma-c-cytokine activity
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102707650B1 (ko) 2017-04-07 2024-09-19 바이오니즈 테라퓨틱스, 아이엔씨. 감마-c-사이토카인 활성의 안정한 조절자
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
JP7386161B2 (ja) * 2017-12-19 2023-11-24 ブレイズ バイオサイエンス， インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
BR112021021878A2 (pt) 2019-05-03 2022-01-18 Bioniz Llc Modulação dos efeitos de sinalização da gama-c-citocina para tratamento da alopecia e distúrbios associados
US20250281583A1 (en) * 2021-10-13 2025-09-11 Modernatx, Inc. Composition of mrna-encoded il15 fusion proteins and methods of use thereof
US20240043499A1 (en) * 2022-08-07 2024-02-08 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002061A1 (en) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Novel lipoprotein-based drug-delivery systems
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
WO1996027392A1 (en) 1995-03-08 1996-09-12 The Scripps Research Institute Antigen presenting system and methods for activation of t-cells
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
WO2002038609A2 (en) * 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
AU2008201887B2 (en) * 2000-11-10 2011-06-30 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
WO2005070400A1 (en) 2004-01-15 2005-08-04 Mount Sinai School Of Medicine Methods and compositions for imaging
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
CA2657277C (en) * 2006-07-13 2015-11-24 Upperton Limited Process for preparing particles of proteinaceous material
KR100817024B1 (ko) 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
EP2305309A2 (en) 2008-06-13 2011-04-06 Proyecto de Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds

Also Published As

Publication number Publication date
WO2011070214A8 (es) 2011-09-29
RU2597989C2 (ru) 2016-09-20
CA2783876C (en) 2018-04-03
WO2011070214A3 (es) 2011-08-04
CN102753574B (zh) 2015-05-20
EP2511294B1 (en) 2014-02-26
ES2463016T3 (es) 2014-05-27
RU2012129208A (ru) 2014-01-20
AU2010329805A1 (en) 2012-07-05
MX2012006691A (es) 2013-02-26
BR112012013868A2 (pt) 2017-01-10
EP2511294A2 (en) 2012-10-17
CA2783876A1 (en) 2011-06-16
BR112012013868A8 (pt) 2017-12-26
JP5784626B2 (ja) 2015-09-24
JP2013513377A (ja) 2013-04-22
US20120244118A1 (en) 2012-09-27
WO2011070214A2 (es) 2011-06-16
CN102753574A (zh) 2012-10-24
US8771664B2 (en) 2014-07-08

Similar Documents

Publication Publication Date Title
WO2011070214A8 (es) Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral
IL272817A (en) New preparations and methods for the treatment of vaccine-related diseases
IN2012DN00446A (enExample)
IN2012DN01920A (enExample)
MX2009011500A (es) Anticuerpos anti-mdl-1.
IN2012DN02736A (enExample)
MX2020012426A (es) Anticuerpos anti-cd38.
GB2464887A (en) Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
PH12012501549A1 (en) Cd127 binding proteins
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
TN2011000374A1 (en) Antibody molecules having specificity for human ox40
MX354481B (es) Anticuerpos dkk1 y métodos de uso.
EA201001691A1 (ru) Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
SG179203A1 (en) Novel arylated camphenes, processes for their preparation and uses thereof
NZ594347A (en) Antibodies against human tweak and uses thereof
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
AU2017221784B2 (en) Novel compositions and methods for the treatment of immune related diseases
ES2362062B1 (es) Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.
AU2014256372B2 (en) New compositions for treating CMT and related disorders
UA101988C2 (ru) АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА II ТИПА ТРАНСФОРМИРУЮЩЕГО ФАКТОРА РОСТА БЕТА (TGFβRII)
PH12013501424B1 (en) Anti-cd38 antibodies
NZ600935A (en) Pythium immunotherapy

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ NEW CONJUGATES AND COMPOSITIONS FOR IMMUNOTHERAPY AND ANTI-TUMORAL TREATMENT

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BERRAONDO LOPEZ, PEDRO; FIORAVANTI, JESSICA; MEDINA ECHEVERZ, JOSE; MELERO BERMEJO, IGNACIO JAVIER; OCHOA NIETO, MARIA DEL CARMEN; PALAZON GARCIA, FRANCISCO DE ASIS; BULFONE-PAUS, SILVIA AND DUITMAN, ERWIN HANS

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired